| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | February 26, 2024 |
| Accession Number: | 0001539497-24-000584 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/16/2022 | $5.00 | Buy | Ladenburg Thalmann |
SC 13G/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13G/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13D/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
Gainers Minerva Surgical (NASDAQ:UTRS) shares increased by 111.8% to $0.42 during Friday's regular session. As of 13:30 EST, Minerva Surgical's stock is trading at a volume of 85.0 million, which is 3814.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $74.9 million. CNS Pharma (NASDAQ:CNSP) stock rose 20.44% to $2.18. CNS Pharma's stock is trading at a volume of 1.6 million shares as of 13:30 EST. This is 48.5% of its average full-day volume over the last 100 days. The company's market cap stands at $9.0 million. Kala Pharmaceuticals (NASDAQ:KALA) stock moved upwards by 18.57% to $17.62. As of 13:30 EST, this security is trading
Gainers Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) shares jumped 143% to $0.45 after the company announced it received agreement from the FDA on its proposed single confirmatory Phase 3 study of AR-301 and the clinical study design. Bluejay Diagnostics, Inc. (NASDAQ:BJDX) gained 67% to $0.3225. VIQ Solutions Inc. (NASDAQ:VQS) shares jumped 49.1% to $0.3474. Marker Therapeutics, Inc. (NASDAQ:MRKR) climbed 31% to $1.73 after the company reported pre-clinical data of its MT-601 multiTAA-specific T cell product candidate MT-601 in lymphoma cells. Tenax Therapeutics, Inc. (NASDAQ:TENX) rose 30% to $0.4151. Tenax Therapeutics achieved major milestone as USPTO granted notice of allowance fo
Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) shares increased by 98.9% to $0.37 during Wednesday's pre-market session. The market value of their outstanding shares is at $13.2 million. VistaGen Therapeutics (NASDAQ:VTGN) stock increased by 38.98% to $0.19. The market value of their outstanding shares is at $40.8 million. Marker Therapeutics (NASDAQ:MRKR) shares increased by 30.83% to $1.74. The market value of their outstanding shares is at $15.3 million. Tenax Therapeutics (NASDAQ:TENX) stock moved upwards by 25.06% to $0.4. The market value of their outstanding shares is at $8.7 million. Freeline Therapeutics (NASDAQ:FRLN) shares moved upwards by 15.99% to $2.9. The market value of th
- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - - Charity Scripture, MS, PharmD, appointed Chief Development Officer effective December 1, 2021 - HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2021 and provided an operational update. "In the third quarter, Bellicum broadened the potential impact of its CaspaCIDe technology through an additional licensing agreement with MD Anderson," said Rick Fair, President and
Ladenburg Thalmann initiated coverage of Bellicum Pharmaceuticals with a rating of Buy and set a new price target of $5.00
15-12G - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
EFFECT - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
EFFECT - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
4 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
3 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
4/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. The trials for BPX-601 and BPX-603 are being discontinued following the Company's assessment of the risk/benefit profile of BPX-601 in combination with rimiducid. The most recent patient treated in the Phase 1/2 trial of BPX-601 in metastatic castration-resistant prostate cancer (mCRPC) experienced serious immune-mediated adverse events including Grade 4 cytokine rel
Biochemical and radiographic responses reported in first two cohorts of dose escalation in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients PSA50 or greater responses in 50% of patients Responses observed in patients with visceral, nodal and bone involvement HOUSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today will present early Phase 1 results for BPX-601 at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco and virtually. The poster titled "Early Results from a Phase 1, Multicent
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of January 31, 2023. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $1.14 per share and vest over four years, with 25% of the shares vesting on the one-year a